Article
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
The New England journal of medicine - 15 May 2014
Kowdley Kris V, Gordon Stuart C, Reddy K Rajender, Rossaro Lorenzo, Bernstein David E, Lawitz Eric, Shiffman Mitchell L, Schiff Eugene, Ghalib Reem, Ryan Michael, Rustgi Vinod, Chojkier Mario, Herring Robert, Di Bisceglie Adrian M, Pockros Paul J, Subramanian G Mani, An Di, Svarovskaia Evguenia, Hyland Robert H, Pang Phillip S, Symonds William T, McHutchison John G, Muir Andrew J, Pound David, Fried Michael W
Abstract excerpt
BACKGROUND: High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir. This study examined 8 weeks of treatment with this regimen. METHODS: In this phase 3, open-label study, we randomly assigned 647 previously untreated patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.